Trading Statement

NMT Group PLC
09 December 2003

9 December 2003

                                 NMT Group PLC

                                 Trading Update

NMT Group, the manufacturer of retractable devices to prevent needlestick
injury, announces that due to insufficient forward orders it will cease
manufacture  at its production facility in Livingston, Scotland with immediate
effect.  During the next three months, NMT will be undertaking a significant
cost-restructuring programme including redundancies.

In the short to medium term the company will continue to focus its commercial
activities on the licensing of its second-generation intellectual property and
the development of its pre-filled safety needle unit technology.  NMT remains in
discussion with several partners with regard to the licensing of its
second-generation syringe technology.  NMT's cash position remains healthy and
the directors are encouraged by the potential of NMT's range of pre-filled
safety needle units, about which the company is currently in discussion with
several leading pharmaceutical companies.

Roy Smith, Chief Executive Officer, said:

'Despite the significant efforts to secure additional business the 2004 forward
order book leaves us no option but to cease the manufacture of our first
generation syringe technology and close our production facility at Livingston.
 This decision is particularly hard given the excellent improvements in
productivity achieved throughout the calendar year.'


Enquiries:
NMT Group PLC
Roy Smith, Chief Executive Officer                   Tel: [phone]
Gerard Cassels, Finance Director                     Tel: [phone]

Financial Dynamics                                   Tel: [phone]
David Yates / Sarah MacLeod


                      This information is provided by RNS
            The company news service from the London Stock Exchange